Broadtree Partners Closes $240M Continuation Fund on Three Assets

Broadtree Partners closed a $240 million continuation fund in late 2024, transferring three portfolio companies from an aging fund into a new vehicle that gave limited partners a choice: cash out now or ride along for what the firm expects will be another value-creation cycle.

The New York-based mid-market firm structured the transaction with Whitehorse Capital as lead investor, creating liquidity for existing LPs while retaining operational control of companies it believes still have significant runway. Roughly 52% of eligible LP equity rolled into the new fund — a meaningful vote of confidence in Broadtree's thesis that these assets weren't ready for traditional exit paths.

Continuation vehicles have evolved from niche restructuring tools into a standard feature of the private equity toolkit, particularly as funds from the 2015-2018 vintage years hit their 10-year mark without clear M&A or IPO windows. What makes this deal notable isn't the mechanism — it's the multi-asset approach and the rollover rate, both of which suggest LPs saw more upside in staying than in taking liquidity at this valuation.

The three companies involved weren't disclosed in Broadtree's announcement, but the firm's historical focus areas — business services, niche industrials, and specialized distribution — offer clues. These are the kinds of businesses that can compound value over extended holds but don't naturally attract strategic buyers or justify IPOs at sub-$500 million enterprise values. In other words: good businesses trapped in the wrong exit environment.

Whitehorse Capital, a secondaries investor that's built its reputation on GP-led transactions, anchored the new vehicle. The firm has been particularly active in the continuation fund space over the past 24 months, a period when traditional secondaries volume softened but GP-led deal flow surged.

The mechanics are straightforward: Whitehorse and other new investors purchased the assets from Broadtree's existing fund at a negotiated valuation, providing cash to LPs who wanted out. LPs who believed in the assets' continued appreciation rolled their stakes into the new fund on the same terms as the incoming investors. Broadtree continues managing the companies, now with a reset fund timeline and fresh capital for add-ons or operational investment.

What's less straightforward is the valuation negotiation. Continuation funds create an inherent tension: the GP wants a valuation high enough to give exiting LPs a decent return, but low enough that new investors see meaningful upside. Get it wrong and you either alienate your LP base or fail to attract outside capital. The 52% rollover rate suggests Broadtree threaded that needle — high enough that staying in felt like the right call, but not so high that Whitehorse walked away.

Industry data shows rollover rates on continuation funds typically range between 40% and 70%, with higher rates generally signaling either strong LP confidence or limited alternative liquidity options. Broadtree's figure sits in the middle of that band — not a landslide endorsement, but well above the threshold where the transaction starts to look like a forced sale.

Most continuation funds focus on a single crown-jewel asset — the one portfolio company that's performed well enough to justify an extended hold and attract outside capital. Broadtree bundled three. That's harder to pull off, both structurally and politically.

Structurally, pricing three assets simultaneously means negotiating three separate valuations with LPs who may have different views on each company's prospects. An LP bullish on Asset A but skeptical of Asset B has to choose between full liquidity or full rollover — there's no à la carte option. That complexity typically pushes rollover rates down relative to single-asset deals.

Politically, multi-asset continuation funds can feel like the GP is dodging accountability. If one of the three companies is struggling, bundling it with two winners lets the GP extend the hold on an asset that should probably be written down. LPs know this dynamic, which is why they scrutinize multi-asset deals more closely than single-asset transactions.

That Broadtree cleared 50% on a three-asset deal suggests either strong underlying performance across all three companies or a valuation discount steep enough to make the risk-reward compelling for both existing and new investors. Probably some combination of both.

For LPs, continuation fund elections are rarely easy calls. Staying in means doubling down on the GP's judgment and accepting another multi-year lockup. Taking liquidity means crystallizing a return that may look modest compared to what the next hold period could generate — but it also means certainty in an uncertain market.

Broadtree Partners operates in the lower-mid to traditional mid-market, typically investing $20 million to $75 million in equity per deal. The firm targets companies with $10 million to $50 million in EBITDA — a segment that's attracted significant competition over the past decade but remains fragmented enough for specialized investors to find differentiated angles.

The firm's strategy emphasizes operational improvement and buy-and-build, which translates to longer hold periods than pure financial engineering plays. That orientation makes continuation funds a natural fit: if you're three years into a five-year value-creation plan when the fund hits year nine, selling to a strategic or another PE firm means leaving value on the table or handing your playbook to a competitor.

Broadtree hasn't been a prolific deal announcer — the firm keeps a relatively low profile compared to megafund peers — but its focus on operational value creation aligns with the kinds of businesses that work well in continuation structures. These aren't software platforms that can scale overnight or consumer brands that can be flipped to strategics. They're industrial services businesses, niche manufacturers, and B2B distributors that compound steadily but don't offer obvious exit catalysts on a fund timeline.

That profile creates a structural mismatch with traditional fund lifecycles, which is exactly why continuation funds exist. The question is whether this becomes a one-off solution for aging investments or a repeatable part of Broadtree's exit strategy going forward.

If this transaction performs — meaning the three companies deliver the value creation Broadtree promised and LPs who rolled see strong distributions within the new fund's lifecycle — expect the firm to lean on continuation vehicles again. If it doesn't, LPs will remember and rollover rates on future deals will suffer.

Continuation funds cut both ways when it comes to a GP's reputation. Done well, they demonstrate creativity, conviction, and the ability to manufacture liquidity in tough markets. Done poorly, they look like a bailout for underperforming investments and erode trust with LPs who feel like they're being asked to re-up on assets that should've exited already.

Broadtree's next flagship fundraise will be the real test. LPs will scrutinize the performance of the continuation fund assets, the returns delivered to those who took liquidity, and whether the multi-asset structure was truly justified by the companies' potential or simply a convenient way to clear three positions at once.

Broadtree's deal is part of a wider trend. GP-led secondaries — the category that includes continuation funds — accounted for roughly 55% of total secondaries volume in 2023, up from under 30% a decade ago. That shift reflects both the maturation of the tool and the lack of attractive exit alternatives for funds hitting the end of their investment periods.

Traditional exits have been constrained since late 2022. M&A volumes are down, strategic buyers are cautious, and IPO windows remain largely closed for anything outside the largest, highest-growth companies. That's left GPs with aging portfolios and LPs demanding liquidity on predictable schedules.

Continuation funds solve that tension, but they also introduce new dynamics. When GPs can extend holds unilaterally by finding a secondaries buyer willing to anchor a new fund, the pressure to maximize value within the original fund timeline diminishes. That's good for long-term value creation but potentially problematic for LPs who invested with the expectation of a 5-7 year fund life.

The counterargument from GPs is that continuation funds aren't unilateral — LPs get a choice, and if the rollover rate is high, that's market validation of the extended hold thesis. Which is true, up to a point. But the choice between liquidity at an uncertain valuation and staying invested with no clear timeline isn't always the choice LPs wanted when they committed capital.

The SEC has been watching the continuation fund boom closely, particularly around potential conflicts of interest when GPs set valuations, select which LPs get early looks at terms, and benefit from extended management fees. No major enforcement actions have landed yet, but the scrutiny is real and several large firms have quietly tightened their internal policies around CF pricing and governance.

Broadtree's deal doesn't appear to have any unusual structural red flags, but the broader market will keep watching how these transactions are documented, how valuations are determined, and whether LPs who roll consistently outperform those who take liquidity. If the data starts showing that continuation funds systematically favor GPs over LPs, expect regulatory intervention.

Assuming Broadtree's thesis is correct — that these three companies have genuine operational upside that justifies an extended hold — the continuation fund structure buys time for initiatives that wouldn't fit into the 12-18 months before a traditional exit.

That could mean finishing a buy-and-build strategy that's halfway complete, integrating a recent acquisition that hasn't yet shown up in the numbers, investing in systems or infrastructure that will take two years to pay off, or simply waiting for market multiples to recover in a sector that's temporarily out of favor.

The specifics matter. If Broadtree is using the continuation fund to finish a roll-up that's already showing strong integration synergies, LPs who rolled are probably in good shape. If it's using the CF to paper over execution issues or wait out a cyclical downturn with no active value plan, the next few years could be rough.

The firm's announcement emphasized continued value creation and operational improvement, which is what every GP says in these situations. The proof will come in the portfolio company performance data over the next 12-24 months.

The 48% of LPs who elected liquidity received cash at the transaction valuation. For them, the deal is done — their returns are locked, and they've moved on. But those returns will be scrutinized, particularly if the assets that rolled into the continuation fund perform well.

If the continuation fund ultimately exits the three companies at materially higher valuations — say, 1.5x to 2x the CF entry price — the LPs who cashed out will have left significant money on the table. That's not necessarily Broadtree's fault (LPs made their own choice), but it will color future CF elections. Once LPs see peer institutions earn outsized returns by staying in, they'll be more reluctant to take liquidity on the next deal.

Conversely, if the continuation fund struggles and the companies exit below the entry valuation, LPs who took liquidity will look prescient and rollover rates on Broadtree's future CFs will plummet.

That dynamic creates a weird incentive structure: GPs want high rollover rates to validate their thesis and minimize the discount to new investors, but they also need exiting LPs to feel like they got a fair shake. Thread that needle poorly and the whole continuation fund strategy falls apart.

Broadtree didn't disclose which three portfolio companies are in the continuation fund, which is standard practice but frustrating for anyone trying to assess the deal's merits. Without knowing the assets, it's impossible to evaluate whether the extended hold makes strategic sense or whether this is just a creative way to defer a write-down.

The firm's historical deal activity offers some clues. Broadtree has invested in business services platforms, industrial distribution companies, and niche manufacturers — all categories that can work well in continuation structures if the underlying businesses are solid but the exit timing is off.

If the three companies are profitable, growing, and genuinely positioned for value creation over the next 3-5 years, the continuation fund is a smart move. If one or more are stagnant or subscale, bundling them with stronger assets to get a deal done is a red flag.

LPs who rolled presumably did their own diligence on the underlying companies, which suggests they believe in the assets. But the lack of public detail means outsiders can't assess whether this is a high-conviction extension or a well-packaged rescue.

The Broadtree continuation fund is now live, which means the next 12-24 months will determine whether the structure delivered on its promises. Key indicators to track:

Portfolio company performance. Are the three assets growing revenue and EBITDA? Are they making acquisitions or investing in operational improvements that justify the extended hold? If financial performance stalls, the CF thesis falls apart.

Exits and distributions. Continuation funds typically target a 3-5 year hold period, though some extend longer. If Broadtree starts exiting the companies within 36 months at strong multiples, LPs who rolled will be vindicated. If the fund is still sitting on the assets in year five with no clear exit path, expect frustration.

Broadtree's next flagship fundraise. The firm's ability to raise its next fund will partially depend on how this continuation fund is perceived. High rollover rates and strong subsequent performance will help. Low distributions and prolonged holds will hurt.

Broader continuation fund market dynamics. If GP-led secondaries volume continues growing and rollover rates stay high, continuation funds become a permanent fixture of the exit toolkit. If the market softens or regulatory scrutiny intensifies, the window could narrow.